Evidence map›Paper›PMID 33209305›Full record

ArticleEvolution, medicine, and public health2020

Effect of drug dose and timing of treatment on the emergence of drug resistance

Mónica M Acosta, Joshua T Bram, Derek Sim, Andrew F Read

Open access · goldAbstract read
In one paragraph

Article in Evolution, medicine, and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Competitive suppression and release in artemisinin-resistantEvolution, medicine, and public health · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mónica M AcostaDepartment of Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA.
Joshua T BramDepartment of Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA.
Derek SimDepartment of Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA.
Andrew F ReadDepartment of Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA.
Pennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere is a significant interest in identifying clinically effective drug treatment regimens that minimize the METHODOLOGY: In a series of experiments, we measured the emergence of atovaquone-resistant mutants of

resultsThe likelihood of high-level resistance emergence increased with atovaquone dose. When varying the timing of treatment, treating either very early or late in infection reduced the risk of resistance. When we varied starting inoculum, resistance was more likely at intermediate inoculum sizes, which correlated with the largest population sizes at time of treatment. CONCLUSIONS AND IMPLICATIONS: (i) Higher doses do not always minimize resistance emergence and can promote the emergence of high-level resistance. (ii) Altering treatment timing affects the risk of resistance emergence, likely due to the size of the population at the time of treatment, although we did not test the effect of immunity whose influence may have been important in the case of late treatment. (iii) Finding the 'right' dose and 'right' time to maximize clinical gains and limit resistance emergence can vary depending on biological context and was non-trivial even in our simplified experiments. LAY SUMMARY: In a mouse model of malaria, higher drug doses led to increases in drug resistance. The timing of drug treatment also impacted resistance emergence, likely due to the size of the population at the time of treatment.

Indexed as

de novodrug resistancedrug treatment timingevolutionin vivoPlasmodium chabaudipopulation size, drug dose

Identifiers

PMID33209305
PMCPMC7652304
OpenAlexW3033893517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.